ArticleCureus2025
A Rare Cause of Intestinal Obstruction: Invasive Lobular Breast Carcinoma Metastasizing to the Ileocecal Valve.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular carcinoma (ILC) has a higher propensity for gastrointestinal metastases compared to invasive ductal carcinoma (IDC). We present the case of a 65-year-old woman with metastatic ILC who developed intestinal obstruction due to ileocecal metastases 30 months after undergoing total mastectomy and adjuvant therapy for left-sided breast cancer (BC). Abdominal computed tomography (CT) demonstrated a transition point at the ileocecal valve. Surgical resection was performed to relieve the small bowel obstruction, and histopathology confirmed metastatic ILC with receptor discordance compared to the primary tumor. This case highlights the diagnostic and therapeutic challenges of intestinal metastases from BC, including receptor conversion and resistance to therapy. Molecular profiling and tailored treatment are crucial for optimal management of complex metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.